Carnyx Team

Patrick T. Gunning is a Professor of Molecular Therapeutics at the University of Glasgow, Professor of Chemistry at the University of Toronto and previously a Canada Research Chair in Medicinal Chemistry, founder and inaugural Director of Centre for Medicinal Chemistry.

Dr. Gunning earned his Ph.D. from the University of Glasgow and completed postdoctoral studies at Yale University. He has authored over 140 research publications and received numerous accolades, including the Boehringer Ingelheim Young Investigator Award, the RSC MedChemComm Emerging Investigator Lectureship, and recognition as one of Canada's Top 40 Under 40. Patrick is a Fellow of the Royal Society for Chemistry.

Beyond academia, he has co-founded multiple biotech companies, including Janpix Inc., publicly traded Centessa Pharmaceuticals ($CNTA), Dunad Therapeutics, Dalriada Drug Discovery, HDAX Therapeutics, and Carnyx Therapeutics, collectively securing over $100 million in funding. In 2021, Dunad Therapeutics entered a strategic collaboration with Novartis, potentially worth up to $1.3 billion, to develop next-generation oral targeted protein degrader therapies.

Dr. Mark Lindsay is a Doctor of Chiropractic and graduate of Palmer Chiropractic College, renowned for his work with Super Bowl Champions, Stanley Cup Champions, Major League Baseball Championship teams and elite athletes including multiple World and Olympic Champions.

Dr. Lindsay has worked extensively with elite athletes and teams over the past 35 years to enhance performance and reduce injury risk. Dr. Lindsay is a member of the College of Chiropractors of Ontario; a Diplomate with the American Chiropractic Neurology Board, a member of the Ontario Chiropractic Association, a member of the Colorado Chiropractic Association and a 2025 PhD Candidate in the Neuroscience Program at Queens University in Kingston, Ontario.

Dr. Lindsay has completed over 2500 hours of course work through the Carrick Institute for Graduate Studies and has spent the past two decades studying under the late French osteopath, Dr. Guy Voyer in the Fascia Fellowship Program. Mark is the author of the book “Fascia: Clinical Applications for Health and Human Performance” along with 10 research publications.

Mark is founder of Dr. Mark Lindsay Chiropractic Professional Corp, Lindsay Sports Therapy and co-founder of multiple biotech companies including: Carnyx Therapeutics, Kelvin Therapeutics and Entourage Diagnostics. Mark is also a Research Fellow with the Steadman Philippon Research Institute in Vail, Colorado. Dr. Lindsay was named the “Outstanding Field Doctor” by Canadian Chiropractic Sports Fellowship in 1996, following his work with double Olympic Champion and World Record Holder, Donovan Bailey.

With over three decades of executive leadership and entrepreneurial experience, Terry Butler has built a distinguished career spanning finance, biotechnology, e-commerce, and consumer products. From 2018 to 2022, he served as Owner and CEO of Hilton Head Oils, where he led the company through product development, brand expansion, and operational growth. Prior to that, he was CEO of Gemini Investment Corp (2016–2017), focusing on early-stage investment strategies and portfolio management.

From 2014 to 2015, Terry was CFO of Cala, Inc., bringing financial discipline and strategic oversight to the growing consumer brand. He previously served on the Board of Directors and as CFO and consultant at Etapestry.com (2000–2007), a pioneering cloud-based fundraising platform that helped transform digital donor engagement.

Terry also co-founded StemSource, Inc. and served as its COO and CFO from 2000 to 2003, helping position the company at the forefront of stem cell technology. Before that, he held similar leadership roles at CellSource, Inc. (1997–1998), further demonstrating his expertise in emerging life sciences ventures.

From 1992 to 1997, he served as Director of Strategic Planning at Werner Co., one of North America’s largest manufacturers of ladders and climbing equipment, where he played a critical role in long-term growth initiatives. Earlier in his career, Terry was Vice President at PaineWebber (now UBS Securities) from 1986 to 1990, where he developed a strong foundation in capital markets and investment banking that continues to inform his strategic approach today.

Mark Bell is a seasoned medicinal chemist with over two decades of experience spanning the biotech industry, contract research organizations (CROs), and academic drug discovery. He is the co-founder and Chief Technology Officer of Tay Therapeutics, where he has led the discovery and development of several innovative therapeutic candidates.

Mark spearheaded the discovery of Repibresib, a topical soft-drug pan-BET inhibitor currently in Phase 2a clinical trials for vitiligo, and VYN202, a BD2-selective oral BET inhibitor in Phase 1b trials for psoriasis. He also led the development of TAY-R1, an oral small molecule gene therapy targeting rare genetic diseases such as recessive dystrophic epidermolysis bullosa and Duchenne muscular dystrophy.

Mark is a co-founder of Hawkhill Therapeutics, focused on obesity and sarcopenia, and Entourage Diagnostics focused on proteomic biomarker analysis. During his time at the integrated drug discovery CRO Dalriada, he led the delivery of a preclinical candidate for postoperative pain for Antibe Therapeutics. While working with the Drug Discovery Unit at the University of Dundee he led on the discovery of a topical soft-drug SMO inhibitor preclinical candidate for Gorlin syndrome.  At Almac Discovery, he contributed to the development of Phase 1b oncology candidates targeting Wee1 and Akt. He has provided strategic consulting for KelticPharma Therapeutics on their PfCLK3 malaria program enabling successful proof-of-concept in the SCID mouse model and transition to LO.

Mark is an inventor on 16 published patents across inflammation, rare diseases, and oncology therapeutic areas, reflecting his deep commitment to advancing translational science and improving patient outcomes.